Hepatitis A Virus (HAV) Quick Reference Guide for Health Care Professionals
On this page:
Report to MDH
Signs and Symptoms
Trends and Statistics
Download PDF version formatted for print:
Hepatitis A Virus (HAV) Quick
Reference Guide for Health Care Professionals (PDF:35KB/1 page)
to Minnesota Department of Health
||Acute HAV infection (positive
||HAV is an RNA virus in the picornavirus
- May be asymptomatic
- Older persons are more likely to have symptoms.
Symptoms usually occur abruptly and may include fever, tiredness,
loss of appetite, nausea, abdominal discomfort, dark urine, or
- Symptoms generally last less than two months; occasionally,
prolonged or relapsing illness can last up to six months.
- Average incubation period is 28 days (range: 15-50
- Chronic infection does not occur.
- HAV infection confers life-long immunity.
- 15 percent of HAV-infected persons will have prolonged
or relapsing symptoms over a six-month period.
Fecal-oral transmission by:
- person-to-person contact or
- ingestion of contaminated food or water
||Four days before to seven days after onset of jaundice or 14 days after onset of symptoms in the absence of jaundice
- Household contacts of infected persons
- Sexual contacts of infected persons
- Persons, especially children, living in regions
of the United States with high rates of HAV infection
- Travelers to regions where HAV is common, including
Central and South America, Africa, and Asia
- Men who have sex with men
- Injection and non-injection drug users
- HAV vaccine is the best protection.
- For healthy persons 12 months - 40 years of age, hepatitis A vaccine may be given to stop the onset of symptoms in persons exposed within the previous two weeks. For children under 12 months of age and persons over 40 years of age, Immune Globulin (IG) may be given to stop the onset of symptoms in persons exposed within the previous two weeks.
- Hand washing with soap and water after using the
bathroom or changing diapers and before preparing or eating food.
HAV vaccine is recommended for:
- travelers to areas with increased rates of HAV
- men who have sex with men
- injection and non-injection drug users
- persons with chronic liver disease
- persons with clotting-factor disorders (e.g.,
- children living in regions of the U.S. with high
rates of HAV infection
- anyone who wants to be protected from contracting
*HAV vaccine is licensed only for persons 1 year
of age or older
For healthy persons 12 months – 40 years of age hepatitis A vaccine may be given to stop the onset of symptoms in persons exposed within the previous two weeks.
For children under 12 months of age and persons over 40 years of age Immune Globulin (IG) may be given to stop the onset of symptoms in persons exposed within the previous two weeks.
- Occurs in epidemics nationally and locally
- During epidemic years, the number of HAV cases
reported in the U.S. has reached 35,000
- Since the HAV vaccine was licensed in 1995, vaccine
use has increased in the U.S. and morbidity has reached historic
lows. One-third of persons in the U.S. are immune to HAV (i.e.,
have evidence of past infection). Approximately one-third of reported
cases occur among children less than 15 years of age.
- HAV incidence